Quantbot Technologies LP Cyma Bay Therapeutics, Inc. Transaction History

Quantbot Technologies LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$1.72 - $3.39 $2,973 - $5,861	-1,729 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$3.23 - $4.6 $646 - $919	-200 Reduced 10.37%	1,729 $5,000
Q3 2021 Nov 09, 2021	BUY	$3.47 - $4.42 $6,693 - $8,526	1,929 New	1,929 $7,000
Q2 2021 Aug 12, 2021	SELL	$3.94 - $4.92 $90,285 - $112,741	-22,915 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$4.23 - $6.55 $6,556 - $10,152	-1,550 Reduced 6.34%	22,915 $104,000
Q4 2020 Feb 12, 2021	BUY	$5.73 - $9.03 $140,184 - $220,918	24,465 New	24,465 $140,000
Q1 2020 May 13, 2020	SELL	$1.25 - $2.02 $4,896 - $7,912	-3,917 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$1.33 - $5.93 $3,701 - $16,503	-2,783 Reduced 41.54%	3,917 $7,000
Q3 2019 Nov 12, 2019	BUY	$5.12 - $7.21 $20,751 - $29,222	4,053 Added 153.12%	6,700 $34,000
Q2 2019 Aug 13, 2019	BUY	$6.05 - $13.66 $16,014 - $36,158	2,647 New	2,647 $18,000
Q2 2018 Aug 13, 2018	SELL	$10.66 - $14.38 $127,877 - $172,502	-11,996 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$9.0 - $15.16 $107,964 - $181,859	11,996 New	11,996 $155,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.